A recent study suggests that patients who discontinue blockbuster GLP-1 drugs like semaglutide or tirzepatide may regain shed pounds at a significantly accelerated pace than those who end traditional diet and exercise plans.
Findings released in a major medical journal points out that while obese individuals often shed substantial amounts of their total mass while using the jabs, the weight returns at an average rate of 0.8 kg per month after stopping.
"People buying these treatments should be cognizant of the danger of rapid weight regain when the medication concludes," cautioned lead investigator Dr. Susan Jebb.
That rate of regain means a return to starting weight in about one and a half years.
Weighing Approaches
The analysis, which looked at dozens of studies involving thousands of patients, compared the results of GLP-1 agonists with older methods.
Researchers note that individuals who lose weight through lifestyle changes alone typically see a less rapid weight regain—approximately 0.1 kg a month—after stopping.
Explaining the Quick Rebound
Doctors suggest the way of the injections is key to understanding the amplified rebound.
The injections mimic a body's own chemical called GLP-1, which moderates appetite.
"Sustained high doses of GLP-1 concentrations several times higher than the body's typical production could lead to the system to produce less of its own natural hormone, and could diminish responsiveness to its effects," explained Dr. Adam Collins, a nutrition expert.
"Stopping of this medication means appetite is uncontrolled, making excessive eating much more probable."
A Lifelong Issue?
Health authorities advise the injections for people with obesity-related health risks, alongside prescribed diet and exercise modifications.
Many experts contend that, due to the likelihood of relapse, the treatment is often life-long.
This view is reinforced by pharmaceutical companies, who state that the findings "emphasize the persistent character of excess weight," comparing it to managing conditions like high blood pressure.
User Accounts
Users who have stopped the medication describe a intense resurgence of appetite.
"I experienced a switch activating and you become starving," said a patient.
This difficulty is compounded if individuals have not developed sustainable dietary or behavioural modifications during treatment.
Significant Adoption
Figures show that millions of people in the UK have tried weight-loss jabs in the past year, with interest continuing to grow.
- Adoption is greater among females compared to men.
- The middle-aged demographic shows the highest level of interest.
- A large proportion access the medications through private prescriptions rather than the NHS.
In conclusion, clinicians stress that while the jabs are powerful tools for shedding pounds, they are not a magic cure and lasting health benefits relies on integrated behavioural support.
